Amy Rourke
PA-C
Introduction
Location : Boston, MA, USA
Specialty : MASLD
BIO
Amy Rourke PA-C is a physician associate (PA) in outpatient hepatology at Beth Israel Deaconess Medical Center in Boston, Massachusetts. With hepatology experience for more than 20 years, Amy is committed to patient care. Amy received a B.S. in Biology from Boston College where she graduated cum laude. She then went on to complete a Master of Science Physician Assistant Studies degree at Northeastern University. She holds a faculty role with Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) where she also serves on their education committee. Amy is passionate about her patients and provides comprehensive, high quality care across the spectrum of liver disease states including MASH, MASLD, cirrhosis, PBC, PSC, autoimmune hepatitis, viral hepatitis, liver failure, and portal hypertension.
MASH Content Featuring Rourke's, PA-C
Management of Life Style Modification
This video focuses on the comprehensive management of patients with metabolic-associated steatohepatitis (MASH), emphasizing lifestyle modifications, dietary adjustments, and exercise strategies. Key topics include the importance of addressing risk factors like diet, exercise habits, and alcohol intake, as well as referrals to medically supervised weight loss clinics or bariatric surgery for advanced cases. The speaker highlights the benefits of the Mediterranean diet, intermittent fasting, and avoiding ultra-processed foods while discussing the role of resistance training to combat sarcopenia and maintain muscle mass. Practical advice and tailored recommendations ensure a holistic approach to managing MASH and improving patient outcomes.
Watch Now
Third Step of Life Style Management
This video provides a comprehensive overview of emerging pharmacologic treatments for metabolic-associated steatohepatitis (MASH) and their tailored applications based on patient profiles. Topics include FDA-approved therapies, drugs in advanced clinical trials (such as semaglutide and lanifibranor), and the potential for combination treatments targeting both steatohepatitis and fibrosis. The speaker emphasizes the importance of patient-specific approaches considering metabolic profiles, obesity, and diabetes status, alongside lifestyle interventions. Additionally, the video discusses the evolving interdisciplinary care model and highlights the exciting progress in non-invasive testing and treatment advancements for F2-F3 fibrosis.
Watch Now
Approved Medication for MASH/NASH
This video provides detailed guidance on selecting and monitoring patients for emerging therapies targeting advanced fibrosis (F2-F3) in NASH. Key topics include contraindications for patients with cirrhosis, considerations for concomitant medications, and dose adjustments for statins. The video outlines ideal candidates based on specific thresholds for VCTE, MRE, ELF scores, and other non-invasive tests while emphasizing the importance of ruling out portal hypertension and other liver diseases. It also reviews a stepwise monitoring approach, focusing on tolerability at three months and efficacy assessments at six and twelve months, with an emphasis on histologic and non-invasive test improvements.
Watch Now
